List of Current clinical trials based on the Central Clinical Hospital RAS

1. Protocol ID P2-IMU-838-UC: "A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of IMU-838 for Induction and Maintenance Therapy in Moderate-to-severe Ulcerative Colitis".
Sponsor: Immunic AG
Field of study: gastroenterology
Study Period: 2019 -2025
Principal Investigator: MD Alikhanov B.A
Recruitment continues

2. Protocol ID CNTO1275UCO300: "A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis". Phase 3.
Sponsor: Janssen Research & Development, LLC
Field of study: gastroenterology
Study Period: 2015 -2021
Principal Investigator: MD Alikhanov B.A
Recruitment completed.

3. Protocol ID GA28948/51: "Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of Remission) and Safety of Etrolizumab Compared With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors". Phase 3.
Sponsor: Hoffmann-La Roche
Field of study: gastroenterology
Study Period: 2015 -2021
Principal Investigator: MD Alikhanov B.A
Recruitment completed.

4. Protocol ID M14-423: "A multicenter open-label study that evaluates long-term outcomes in treatment with a combination drug containing AVT-450 / ritonavir / AVT-267 (AVT-450 / r / AVT-267) and AVT-333 in combination with ribavirin (RBV) or without it in adult patients with chronic infection caused by genotype 1 of the hepatitis C virus (TOPAZ-1 Study)." Phase 3.
Sponsor: AbbVie INC., USA.
Field of study: hepatology.
Study Period: 2015 - 2021
Principal Investigator: MD Nikitin I.G.
Recruitment completed.

5. Protocol ID V114-025: "Multicenter, randomized, double-blind, active drug-controlled comparison phase 3 study to assess the safety, tolerability and immunogenicity of the V114 vaccine in healthy infants (PNEU-PED-EU-1)". Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Field of study: Pediatrics. Vaccination against pneumococcal infection
Study Period: 2015 - 2021
Principal Investigator: MD, Namazova-Baranova L.S.
Recruitment completed.

6. Protocol ID V114-024: "A multicenter, randomized, double-blind, active-controlled comparison study with a 3-phase study to assess the safety, tolerability and immunogenicity of V114 catch-up vaccination regimens in healthy infants, children and adolescents (PNEU-PLAN)." Phase 3.
Sponsor: Merck Sharp & Dohme Corp.
Field of study: Pediatrics. Vaccination against pneumococcal infection.
Study Period: 2019 - 2022
Principal Investigator: MD, Namazova-Baranova L.S.
Recruitment continues

7. Protocol ID MMH-SU-006: "A multicenter, double-blind, placebo-controlled, randomized clinical trial in parallel groups of the efficacy and safety of Subetta in patients with impaired glucose tolerance." Phase 3.
Sponsor: NPF “Materia Medica Holding” LLC, Russia.
Field of study: Endocrinology, type 2 diabetes
Study Period: 2019 - 2020
Principal Investigator: Ph.D. Gofman A.M.
Recruitment completed.

8. Protocol ID MMH-407-001: "A multicenter, double-blind, placebo-controlled, randomized clinical trial in parallel groups of the efficacy and safety of MMH-407 in the treatment of acute respiratory viral infection." Phase 3
Sponsor: NPF “Materia Medica Holding” LLC, Russia.
Field of study: Internal diseases. ARVI treatment.
Study Period: 2019 - 2020
Principal Investigator: Ph.D. Gofman A.M.
Набор завершен.

9. Protocol ID MMH-407-002: "A multicenter, double-blind, placebo-controlled, randomized clinical trial in parallel groups of efficacy and safety of MMH-407 in the treatment of influenza in outpatients." Phase 3
Sponsor: NPF “Materia Medica Holding” LLC, Russia.
Field of study: Internal diseases. ARVI treatment.
Study Period: 2019 - 2021
Principal Investigator: Ph.D. Gofman A.M.
Recruitment will resume in November 2020

List of Current clinical trials based on the Central Clinical Hospital RAS

10. Protocol ID VNRX-5133-201: "A Phase 3, Randomized, Double-blind, Active-Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults with Complicated Urinary Tract Infections"

Sponsor: VenatoRx Pharmaceuticals, Inc. (VenatoRx) USA

Field of study: Urology. UTI infection.

Study Period: 2020 - 2022

Principal Investigator: Ph.D. Korolev S.V.

Start patient recruitment is expected in April 2020

11. Protocol ID MMH-MAP-002: "A multicenter, double-blind, placebo-controlled, randomized clinical trial in parallel efficacy and safety groups using MMH-MAP for the treatment of cognitive impairment in patients with cerebral infarction in the carotid pool." Phase 3

Sponsor: NPF "Materia Medica Holding" LLC, Russia.

Field of study: Neurology. Stroke.

Study Period: 2019 - 2021

Principal Investigator: MD., neurologist, O. Tyurin

Recruitment completed.